Overcoming self-tolerance to tumour cells.

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immunotherapy shows promise for cancer treatment, including eradicating metastasis.
• Peripheral tolerance and thymic negative selection limit immunotherapy by eliminating self-reactive T cells.
• Tumour antigens are often self-antigens, posing a challenge for T cell activation against cancer.

Purpose of the Study:

• To review strategies for overcoming self-tolerance in anti-tumour immunotherapy.
• To discuss the potential of reprogramming dendritic cells (DCs) and lymphocytes for cancer treatment.

Main Methods:

• Review of existing literature on immunotherapy and self-tolerance mechanisms.
• Exploration of molecular mimicry for T cell activation against tumours.
• Discussion of RNA interference (RNAi) and small interfering RNA (siRNA) for reprogramming immune cells.

Main Results:

• Molecular mimicry can activate tumour-reactive T cells via cross-reactivity with foreign antigens.
• Reprogramming dendritic cells with RNA interference can present self-antigens and activate anti-tumour T cells.
• Small interfering RNA (siRNA) offers a method to modulate DC and lymphocyte functions.

Conclusions:

• Breaking self-tolerance is crucial for effective anti-cancer immunotherapy.
• Reprogramming immune cells, particularly dendritic cells, holds significant potential for enhancing anti-tumour responses.
• Targeted modulation of immune cell function via RNAi presents a novel therapeutic avenue for solid and blood tumours.